Status:
COMPLETED
Study of One Protein Implicated in Wegener Disease
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Wegener's Granulomatosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The investigators recently showed an abnormal expansion of NK-like CD4+ T cells in Wegener's granulomatosis (WG), mainly in the diffuse vasculitis presentation. These cells expressed an assortment of ...
Detailed Description
The investigators will test our hypothesis of "DAP-12 gain-of-function" by quantitative (mRNA and protein) and qualitative (DNA, signaling and cellular activation) analysis of the DAP12 signaling path...
Eligibility Criteria
Inclusion
- Group 1: WG, with granulomatous lesions limited to upper airway or lungs and no evidence of generalized vasculitis ,± biopsy, ± anti-PR3 ANCA
- Group 2: WG with granulomatous lesions plus vasculitis expression (renal, neurological, skin, gut or heart involvement), ± biopsy, ± anti-PR3 ANCA
- Group 3: Necrotizing vasculitis with no granulomatous lesions, ± PAUCI immune glomerulonephritis, ± anti-MPO ANCA
- Group 4: clinical presentation compatible with sarcoidosis, ± biopsy, ± ECA elevated ± tuberculin anergy
Exclusion
- \<18 years
- Pregnancy or breastfeeding
- Absence of signed informed consent
- No affiliation to insurance
Key Trial Info
Start Date :
May 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2014
Estimated Enrollment :
138 Patients enrolled
Trial Details
Trial ID
NCT01167491
Start Date
May 1 2010
End Date
September 1 2014
Last Update
April 21 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medecine Interne Hôpital Saint Louis
Paris, France, 75010